Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.32-1.07%BTC$76,741.00-1.35%ETH$2,255.35-0.25%GOLD$3,956.60+1.48%OIL$96.26-7.55%
Smart Investors Daily
SID Premium
FE

NASDAQ · FEMY

Femasys Inc.

Healthcare · Medical - Instruments & Supplies

$1.37

Down-$0.05 (-3.65%)

Updated Nov 2, 2026, 10:08 PM

SID Score

4.9/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
25.19M
P/E ratio
-1.77
Dividend yield
0.00%
52-week range
$0.33 – $7.60
Volume
95.12K
Avg. volume
8.09M

Price performance · FEMY

FEMY price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

FEMY closed at $1.37 after 20 trading sessions, down 32.18% for the selected period.

Last close
$1.37
Period change
-32.18%
Period low
$1.36
Period high
$2.08
Daily close
View OHLC price history
FEMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.33$1.4099$1.30$1.3795.12K
Oct 29, 2026$1.40$1.44$1.30$1.355110.32K
Oct 28, 2026$1.36$1.44$1.36$1.4163.43K
Oct 27, 2026$1.40$1.46$1.3202$1.37228.77K
Oct 26, 2026$1.49$1.50$1.361$1.41110.57K
Oct 23, 2026$1.59$1.59$1.455$1.50126.3K
Oct 22, 2026$1.66$1.68$1.46$1.56167.72K
Oct 21, 2026$1.66$1.72$1.64$1.6532.51K
Oct 20, 2026$1.65$1.77$1.58$1.6734K
Oct 19, 2026$1.73$1.75$1.56$1.6393.69K
Oct 16, 2026$1.70$1.77$1.60$1.6558.52K
Oct 15, 2026$1.49$1.81$1.46$1.735130.83K
Oct 14, 2026$1.74$1.75$1.465$1.56208.89K
Oct 13, 2026$1.76$1.81$1.67$1.7635.53K
Oct 12, 2026$2.00$2.02$1.71$1.7566.53K
Oct 9, 2026$2.10$2.15$1.92$2.00128.5K
Oct 8, 2026$1.99$2.11$1.94$2.04567.69K
Oct 7, 2026$2.04$2.05$1.96$2.0080.8K
Oct 6, 2026$2.07$2.11$2.01$2.0824.17K
Oct 5, 2026$2.05$2.17$1.99$2.02228.36K

Latest FEMY news

The latest Smart Investors Daily articles mentioning FEMY.

Stock researchCompany · Overview

FEMY research

Overview

Company profile and research snapshot.

Company profile

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
FEMY recent ratings
DateFirmRatingTarget
Aug 18, 2026Lake StreetBuy—
Aug 14, 2026Maxim GroupBuy—
Mar 3, 2026Lake StreetBuy—
Nov 20, 2025Laidlaw & Co.Buy—
Aug 11, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Femasys Partners with SandsRx Pharmacy to Support FemaSeed® Fertility Portfolio Launch to OB/GYNs

First in a planned network of specialty pharmacy partnerships provides medication coordination and preferred pricing for OB/GYNs and their patientsATLANTA, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today an agreement with SandsRx Pharmacy, marking the firs

Yahoo · Oct 14, 2026

Femasys Doubles Enrolling Sites in FemBloc FINALE Pivotal Trial for Non-Surgical Permanent Birth Control

-- Twelve academic and private clinical sites across the U.S. broaden patient access to the pivotal trial as Femasys advances FemBloc toward potential FDA approval --ATLANTA, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator developing transformative fertility and non-surgical permanent birth control solutions designed to improve the standard of care, expand access, and reduce costs for women worldwide, announced today that it has doubled the number of

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By